Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

机译：Guselkumab治疗牛皮癣：III期试验综述

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

IntroductionInterleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway.

机译：简介白介素（IL）-23抑制剂是一类新型的生物制剂，目前正在治疗中至重度牛皮癣的临床试验中。目前正在进行IL-23受体单克隆抗体guselkumab的III期研究。

著录项

期刊名称 Dermatology and Therapy
作者
Mio Nakamura; Katherine Lee; Caleb Jeon; Sahil Sekhon; Ladan Afifi; Di Yan; Kristina Lee; Tina Bhutani;
展开▼
作者单位

展开▼
年(卷),期 2017(7),3
年度 2017
页码 281–292
总页数 12
原文格式 PDF
正文语种
中图分类皮肤病学与性病学;
关键词
Anti-interleukin-23 Biologics Guselkumab Phase III Psoriasis VOYAGE;

机译：Anti-interleukin-23;Biologics;Guselkumab;III期;牛皮癣;航行;

相似文献

外文文献
中文文献
专利

1. Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials [J] . Mio Nakamura, Katherine Lee, Caleb Jeon, Dermatology and Therapy . 2017,第3期

机译：Guselkumab治疗牛皮癣：III期试验综述
2. Review of phase III III trial data on IL IL ‐23 inhibitors tildrakizumab and guselkumab for psoriasis [J] . Amin M., Darji K., No D.J., Journal of the European Academy of Dermatology and Venereology: JEADV . 2017,第10期

机译：综述III III III试验数据IL IL -23抑制剂TINDRAKIZUMAB和Guselkumab用于牛皮癣
3. Review of phase III III trial data on IL IL ‐23 inhibitors tildrakizumab and guselkumab for psoriasis [J] . Amin M., Darji K., No D.J., Journal of the European Academy of Dermatology and Venereology: JEADV . 2017,第Suppla2期

机译：综述III III III试验数据IL IL -23抑制剂TINDRAKIZUMAB和Guselkumab用于牛皮癣
4. Statistical Methods for Combining Clinical Trial Phases II And III [C] . Nigel Stallard, Susan Todd International Conference on Statistics in Health Sciences . 2007

机译：结合临床试验阶段II和III的统计方法
5. Examination of novel statistical designs for phase II and phase III clinical trials. [D] . Ayanlowo, Ayanbola Olajumoke. 2007

机译：检验II期和III期临床试验的新颖统计设计。
6. Short-Term Efficacy and Safety of IL-17 IL-12/23 and IL-23 Inhibitors Brodalumab Secukinumab Ixekizumab Ustekinumab Guselkumab Tildrakizumab and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials [O] . Fan Bai, Gang Gang Li, Qingmin Liu, 2019

机译：IL-17IL-12 / 23和IL-23抑制剂BrodalumabSecukinumabIxekizumabUstekinumabGuselkumabTildrakizumab和Risankizumab治疗中度至重度斑块状牛皮癣的短期疗效和安全性：系统评价和随机对照试验的网络元分析
7. Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS) [O] . D. Thaçi, A. Pinter, M. Sebastian, 2020

机译：Guselkumab在患者中优于富马酸酯，患者中度至严重的斑块牛皮癣是天真的系统性治疗：随机，活性比较器控制阶段试验（Polaris）的结果

Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials

摘要

著录项

相似文献

相关主题

期刊订阅